lcxx11655
Big News Roundup: Xanthic Biopharma Inc. Announces LOI with Licensed Producer, Green Mile Solutions LLC; Lexaria Achieves Significant Breakthrough in Alternative Nicotine Delivery Technology; Isodiol International Signs Agreement to Acquire 19.9% Equity into Leading Canadian Medical Cannabis Clinic
In case you missed it, here is this week’s life science big news roundup:
Biotech:
- RISE Life Science Corp. Announces Closing $2.2M of Equity Financing
- Kalytera Announces Issuance of Patent Covering the Use of CBD for the Treatment of Severe and Refractory Graft Versus Host Disease
- Xanthic Biopharma Inc. Announces LOI with Licensed Producer, Green Mile Solutions LLC, for Production and Sale of Xanthic-Infused Products in Oregon, Nevada and Ohio
- Isodiol International Inc. Signs Definitive Agreement to Acquire 19.9% Equity into Leading Canadian Medical Cannabis Clinic & Retailer
- Lexaria Achieves Significant Breakthrough in Alternative Nicotine Delivery Technology
To see our previous Life Science Investing Big News Roundups, please click here.
This article is updated each week. Please scroll to the top for the most recent information.
April 13 Big News Roundup: Canntab Announces Completes Amalgamation with Telferscot, Lexaria Receives New US Patent Allowance for Cannabinoid Delivery
In case you missed it, here is this week’s life science big news roundup:
Biotech:
- Naturally Splendid Appoints Douglas Mason as Permanent CEO
- Lexaria Bioscience Corp. Receives New U.S. Patent Allowance for Cannabinoid Delivery and Updates its Expanding Patent Portfolio
- Canntab Therapeutics Announces Completion of Amalgamation with Telferscot Resources
- Kalytera Terminates Pre-Clinical Programs in Bone Disease
April 6 Big News Roundup: Isodiol International Inc. Provides Update on Biosynthesis Pharma Group Acquistion; 3D Signatures Inc. Announces Successful Scoring Model Development and Analytical Validation of the Telo-HL(TM) Test for Hodgkin’s Lymphoma
Biotech:
Genetics:
- 3D Signatures Inc. Announces Successful Scoring Model Development and Analytical Validation of the Telo-HL(TM) Test for Hodgkin’s Lymphoma
To see our previous Life Science Investing Big News Roundups, please click here.